A phase 2 open-label, randomized, non-comparative study to evaluate the safety, tolerability and efficacy of eFT508, in combination with avelumab in microsatellite stable relapsed or refractory colorectal cancer patients

Trial Profile

A phase 2 open-label, randomized, non-comparative study to evaluate the safety, tolerability and efficacy of eFT508, in combination with avelumab in microsatellite stable relapsed or refractory colorectal cancer patients

Planning
Phase of Trial: Phase II

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs Avelumab (Primary) ; EFT 508 (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Effector Therapeutics
  • Most Recent Events

    • 27 Jun 2017 New trial record
    • 20 Jun 2017 According to an Effector Therapeutics media release, this study is expected to begin in the third quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top